These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 23390491)
1. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. Maurer M; Aberer W; Bouillet L; Caballero T; Fabien V; Kanny G; Kaplan A; Longhurst H; Zanichelli A; PLoS One; 2013; 8(2):e53773. PubMed ID: 23390491 [TBL] [Abstract][Full Text] [Related]
2. Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey. Longhurst HJ; Aberer W; Bouillet L; Caballero T; Fabien V; Zanichelli A; Maurer M; Allergy Asthma Proc; 2015; 36(5):399-406. PubMed ID: 26314822 [TBL] [Abstract][Full Text] [Related]
3. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility. Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136 [TBL] [Abstract][Full Text] [Related]
4. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting. Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193 [TBL] [Abstract][Full Text] [Related]
5. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals. Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T; Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099 [TBL] [Abstract][Full Text] [Related]
6. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study. Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405 [TBL] [Abstract][Full Text] [Related]
7. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey. Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179 [TBL] [Abstract][Full Text] [Related]
8. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I; J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444 [TBL] [Abstract][Full Text] [Related]
9. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant. Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O; Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922 [TBL] [Abstract][Full Text] [Related]
10. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Aberer W; Maurer M; Reshef A; Longhurst H; Kivity S; Bygum A; Caballero T; Bloom B; Nair N; Malbrán A Allergy; 2014 Mar; 69(3):305-14. PubMed ID: 24438203 [TBL] [Abstract][Full Text] [Related]
13. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3. Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097 [TBL] [Abstract][Full Text] [Related]
14. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645 [TBL] [Abstract][Full Text] [Related]
15. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study. Campos RA; Valle SO; França AT; Cordeiro E; Serpa FS; Mello YF; Malheiros T; Toledo E; Mansour E; Fusaro G; Grumach AS Sao Paulo Med J; 2014; 132(5):261-5. PubMed ID: 25054967 [TBL] [Abstract][Full Text] [Related]
16. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema. Maurer M; Aberer W; Caballero T; Bouillet L; Grumach AS; Botha J; Andresen I; Longhurst HJ; Clin Exp Allergy; 2022 Sep; 52(9):1048-1058. PubMed ID: 35861129 [TBL] [Abstract][Full Text] [Related]
17. Icatibant as acute treatment for hereditary angioedema in adults. Farkas H Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689 [TBL] [Abstract][Full Text] [Related]
18. Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema. Greve J; Hoffmann TK; Schuler P; Lang S; Chaker A; Bas M Int J Dermatol; 2011 Oct; 50(10):1294-5. PubMed ID: 21950301 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency. Zanichelli A; Mansi M; Azin GM; Wu MA; Periti G; Casazza G; Vacchini R; Suffritti C; Cicardi M Allergy; 2015 Dec; 70(12):1553-8. PubMed ID: 26304015 [TBL] [Abstract][Full Text] [Related]
20. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Zanichelli A; Bova M; Coerezza A; Petraroli A; Triggiani M; Cicardi M Allergy; 2012 Aug; 67(8):1074-7. PubMed ID: 22686628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]